Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enterodiol SCHEMBL31171993 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL31171979 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL11271740 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL31171980 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL2641390 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL30334906 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| SCHEMBL23728328 | 0.87 | ENPP2 (0.44) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL2806235 | 0.87 | TRPA1 (0.59) | ENPP2DRD2TAAR1CYP3A4MMP1 | |
| Enterodiol SCHEMBL2987870 | 0.85 | OPRK1 (0.52) | DRD2DRD1CHRM2CHRM1CHRM3 | |
| SCHEMBL30851571 | 0.85 | CYP3A4 (0.41) | ENPP2DRD2DRD1TAAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116179407-B | Enterococcus faecium and application thereof in bio-conversion of secoisolariciresinol diglucoside | 暨南大学 | 2025-06-24 | — | — | CN | claimed |
| US-12319091-B2 | Acrylated and acylated or acetalized polyol as a biobased substitute for hard, rigid thermoplastic and thermoset materials | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-20250170166-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2025-05-29 | — | — | US | claimed |
| US-20250127199-A1 | COMPOSITION COMPRISING A NUTRIENT AND A TASTE MODULATOR | FIRMENICH SA (CH) | 2025-04-24 | — | — | US | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| EP-4482581-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2025-01-01 | — | — | EP | claimed |
| CN-119111462-A | Method for efficiently producing mammal lignans through ruminant intestinal flora bioconversion | 内蒙古大荒虢蒙生物科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-3606325-B1 | RATIONAL DESIGN OF MICROBIAL-BASED BIOTHERAPEUTICS | GUSTO GLOBAL LLC (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240216296-A1 | POLYPHENOL COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY | EPICEUTICAL LABS LLC | 2024-07-04 | — | — | US | claimed |
| WO-2003061649-A1 | METHOD FOR PREVENTION OF DISEASES IN COELIAC PATIENTS | HORMOS MEDICAL CORPORATION (FI) | 2003-07-31 | — | — | WO | claimed |
| US-20030064938-A1 | METHOD OF PREPARING AND USING COMPOSITIONS EXTRACTED FROM VEGETABLE MATTER FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS | EMPIE MARK (US) | 2003-04-03 | — | — | US | claimed |
| US-20030003168-A1 | Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer | EMPIE MARK (US) | 2003-01-02 | — | — | US | claimed |
| US-20020187211-A1 | METHOD OF PREPARING AND USING COMPOSITIONS EXTRACTED FROM VEGETABLE MATTER FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMPIE MARK (US) | 2002-12-12 | — | — | US | claimed |
| US-6486126-B1 | Antioxidant activity in SDG metabolites | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INCORPORATED (CA) | 2002-11-26 | — | — | US | claimed |
| US-20020168433-A1 | Method of preparing and using compositions extracted from vegetable matter for the treatment of alcoholism | EMPIE MARK (US) | 2002-11-14 | — | — | US | claimed |
| WO-2002080702-A1 | USE OF LIGNANS IN FOODS | UNILEVER N.V. (NL) | 2002-10-17 | — | — | WO | claimed |
| US-6261565-B1 | Method of preparing and using isoflavones | ARCHER DANIELS MIDLAND COMPANY | 2001-07-17 | — | — | US | claimed |
| EP-0906761-A2 | Method of preparing and using phytochemicals | ARCHER-DANIELS-MIDLAND COMPANY (US) | 1999-04-07 | — | — | EP | claimed |
| WO-1997032593-A2 | COMPOSITION CONTAINING ISO-FLAVONOIDS AND LIGNANS | ENERGISER PLC (GB) | 1997-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216296-A1 | POLYPHENOL COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY | FABP2, HDLBP, FABP1 | ENPP2 3304/4885DRD2 3917/4885DRD1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.